Making Tomorrow's Medicines Posts
Earlier this year I was fortunate enough to attend the
When we look at the current trends with what we can refer to as “next generation therapeutics”, whether it be ADCs or cell and gene therapy products, one trend is very clear...
The phrase Knowledge Exchange (KE) describing collaborations between industry and the academic community is recognised as having been a key factor in the development o...
At Cobra we have worked on the development of both naked plasmid DNA and viral gene therapy products for over 20 years. After some rather extended development times, it has been very rewarding to see a number progress out of Phase II
Having worked in the development and production of early stage therapeutics for over 30 years I appreciate as much as anyone that this is often a highly challenging environment, not least with regards to overcoming...
With this year’s Disposables Solutions meeting in Munich rapidly approaching I will focus this blog on some of the issues which I hope will be covered in pre...
One of the most significant challenges facing the Bio-Pharm industry in recent years has been how to reduce development timelines and cost; billons of dollars have been invested in this area, with significant success. This has inclu...
During recent meetings I have attended on single use systems it is apparent that whilst there is the acceptance that single use systems are now mainstream, there are still “growing pains” within the industry. These seem to arise from...
In my last blog ahead of the Disposables Solutions meeting in Munich next month, I said that I would be looking a two key areas, which would feature in the discussion sessions during the meeting, the first being flexible facilities...
Pharma IQ have kindly asked me to chair the forthcoming Disposable Solutions meeting next February in Munich, the meeting will focus as much on discussion sessions as it will on the more formal presentations. As a lead into this meeting, I...
Over recent weeks I have been intrigued to hear some highly negative comments from people outside of the biopharm community on the industries economic value and also concerns regarding the public perception of the potential use of live recombina...
I was fortunate enough to attend the Biotech 2013 Single-Use Technology in Biopharmaceutical Manufacturing meeting in Wädenswill, Switzerland in June, Eric Langer of BioPlan Associates stated “That this should be the last meeting on S...
Throughout my career in the biotech industry I have been fortunate to work on a wide range of cutting edge projects to produce material for first in man studies, whether it be protein fragments, antibody conjugates, DNA, viral, whole cell bacter...
Last month saw the 5th Disposable Solutions meeting take place over two days in Brussels. We had an excellent mix of presentations not just from suppliers thankfully but more importantly from end users looking at the benefi...
The drivers for drug developers seeking to take products into clinical trails are nearly always cited as being cost and time, with timelines often being the over-riding driver. It is therefore not surprising that vast amounts of effort have been...
As everyone in the industry is aware the last 10 years have seen a massive growth in the use of disposables systems for the production of biopharmaceuticals; initially in early stage products but increasingly in commercial products as whole...
As a way of introduction into this column, I should explain my background within the industry and what I would like to achieve. I have been working in the biotechnology & pharmaceutical industry for over 28 years. Initially I began working w...
